close
This ad will auto close in 10 seconds

SC decision on Novartis to benefit poor patients: Pharma cos

Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options".

Supreme Court rejects Novartis cancer drug Glivec patent plea

Glivec, used in treating chronic myeloid leukemia and some other cancers, costs a patient about Rs 1.2 lakh/month, much higher than Rs 8,000 which is the price of the generic drug.